|
US20030157064A1
(en)
*
|
2001-11-09 |
2003-08-21 |
Pascal Neuville |
Chimeric promoters for controlling expression in muscle cells
|
|
US20080044393A1
(en)
*
|
2004-07-16 |
2008-02-21 |
White Robert L |
Retinal dystrophin transgene and methods of use thereof
|
|
US8557969B2
(en)
|
2004-12-01 |
2013-10-15 |
The Regents Of The University Of Michigan |
Compositions and methods for regulating cardiac performance
|
|
WO2008054713A2
(en)
*
|
2006-10-30 |
2008-05-08 |
Thomas Jefferson University |
Tissue specific gene therapy treatment
|
|
US20120322861A1
(en)
*
|
2007-02-23 |
2012-12-20 |
Barry John Byrne |
Compositions and Methods for Treating Diseases
|
|
US20140031417A1
(en)
|
2011-04-06 |
2014-01-30 |
Universite Pierre Et Marie Curie (Paris 6) |
Skeletal muscle-specific enhancer
|
|
MX2014015985A
(es)
|
2012-06-19 |
2015-07-21 |
Univ Florida |
Composiciones y metodos para tratar enfermedades.
|
|
EP2885008B1
(en)
|
2012-08-15 |
2018-11-07 |
University Of Virginia Patent Foundation |
Compositions and methods for treating peripheral arterial disease
|
|
EP3885439A1
(en)
|
2012-12-20 |
2021-09-29 |
Sarepta Therapeutics, Inc. |
Improved exon skipping compositions for treating muscular dystrophy
|
|
EP3760720A1
(en)
|
2013-03-14 |
2021-01-06 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
IL280443B
(en)
|
2013-03-14 |
2022-07-01 |
Sarepta Therapeutics Inc |
Preparations that skip axon for the treatment of muscular dystrophy
|
|
WO2015035364A1
(en)
*
|
2013-09-09 |
2015-03-12 |
University Of Washington Through Its Center For Commercialization |
Proteins for targeting neuronal nitric oxide synthase to muscle sarcolemma and related methods of use
|
|
EP3097197B1
(en)
*
|
2014-01-21 |
2020-12-16 |
Vrije Universiteit Brussel |
Muscle-specific nucleic acid regulatory elements and methods and use thereof
|
|
AU2016227621C1
(en)
|
2015-03-05 |
2020-03-05 |
Peter Und Traudl Engelhorn-Stiftung Zur Förderung Der Lebenswissenschaften |
System for the presentation of peptides on the cell surface
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
CN104894651B
(zh)
*
|
2015-06-29 |
2017-04-12 |
天津诺禾医学检验所有限公司 |
微量起始dna的高通量测序文库构建方法及其所构建的高通量测序文库
|
|
KR102799163B1
(ko)
*
|
2015-09-17 |
2025-04-21 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
Galgt2 유전자 치료 방법 및 물질
|
|
CN109219659B
(zh)
|
2016-04-14 |
2022-09-09 |
贝尼泰克生物制药有限公司 |
用于治疗眼咽型肌营养不良(opmd)的试剂及其用途
|
|
EP4011206B1
(en)
|
2016-06-21 |
2023-11-01 |
The Curators of the University of Missouri |
Modified dystrophin proteins
|
|
WO2019028306A2
(en)
|
2017-08-03 |
2019-02-07 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
|
|
EP3697908A1
(en)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
WO2019079240A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
EP3749756A4
(en)
*
|
2018-02-05 |
2021-12-08 |
Audentes Therapeutics, Inc. |
ELEMENTS OF TRANSCRIPTION REGULATION AND ASSOCIATED USES
|
|
CN120665951A
(zh)
|
2018-02-07 |
2025-09-19 |
吉尼松公司 |
杂合调控元件
|
|
CN112313331A
(zh)
|
2018-04-27 |
2021-02-02 |
沃雅戈治疗公司 |
用于测量aadc病毒载体效力的方法
|
|
MX2020012077A
(es)
|
2018-05-15 |
2021-03-09 |
Voyager Therapeutics Inc |
Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3807404A1
(en)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
WO2020010042A1
(en)
|
2018-07-02 |
2020-01-09 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
|
SG11202103425YA
(en)
|
2018-10-05 |
2021-05-28 |
Voyager Therapeutics Inc |
Engineered nucleic acid constructs encoding aav production proteins
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
JP2022505106A
(ja)
|
2018-10-15 |
2022-01-14 |
ボイジャー セラピューティクス インコーポレイテッド |
バキュロウイルス／Ｓｆ９システムにおけるｒＡＡＶの大規模産生のための発現ベクター
|
|
AU2019381460A1
(en)
|
2018-11-16 |
2021-06-17 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting Utrophin gene
|
|
CN113631225A
(zh)
|
2019-01-18 |
2021-11-09 |
沃雅戈治疗公司 |
用于生产aav颗粒的方法和系统
|
|
EP3931317A4
(en)
|
2019-02-28 |
2023-01-04 |
Benitec IP Holdings Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD)
|
|
KR20210148273A
(ko)
*
|
2019-04-08 |
2021-12-07 |
제네똥 |
근육 발현을 위한 하이브리드 프로모터
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
KR20220012926A
(ko)
|
2019-05-28 |
2022-02-04 |
아스텔라스세이야쿠 가부시키가이샤 |
Dmpk 유전자를 표적으로 하여 근이영양증을 치료하는 방법
|
|
EP4013874A1
(en)
|
2019-08-16 |
2022-06-22 |
Modalis Therapeutics Corporation |
Method for treating muscular dystrophy by targeting lama1 gene
|
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
WO2021202651A1
(en)
|
2020-04-01 |
2021-10-07 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
WO2021211753A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
KR20230022175A
(ko)
|
2020-05-13 |
2023-02-14 |
보이저 테라퓨틱스, 인크. |
Aav 캡시드의 향성 방향변경
|
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
EP4211251A4
(en)
*
|
2020-09-11 |
2025-07-16 |
Aldevron L L C |
MUSCLE-SPECIFIC HYBRID PROMOTER
|
|
WO2022073041A2
(en)
|
2020-09-30 |
2022-04-07 |
NGGT, Inc. |
Dual functional expression vectors and methods of use thereof
|
|
JP2023548746A
(ja)
|
2020-10-13 |
2023-11-21 |
クリヤ セラピューティクス インコーポレイテッド |
サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
|
|
AR124143A1
(es)
|
2020-11-25 |
2023-02-15 |
Astellas Pharma Inc |
Método para tratar la distrofia muscular mediante el direccionamiento al gen dmpk
|
|
EP4284936A1
(en)
|
2021-01-26 |
2023-12-06 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same
|
|
KR20230144588A
(ko)
|
2021-02-12 |
2023-10-16 |
머랜드 파마슈티칼스, 인크. |
저산소증 및 허혈-관련 장애의 치료를 위한 작용제, 조성물 및 방법
|
|
US20240141383A1
(en)
|
2021-03-04 |
2024-05-02 |
Kriya Therapeutics, Inc. |
Viral vector constructs incorporating dna for inhibiting toll like receptors and methods of using the same
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
TW202325263A
(zh)
|
2021-09-14 |
2023-07-01 |
美商雷納嘉德醫療管理公司 |
非環狀脂質及其使用方法
|
|
WO2023044333A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and methods of use thereof
|
|
US20250223376A1
(en)
|
2021-09-20 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US20250084434A1
(en)
|
2022-01-09 |
2025-03-13 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same
|
|
EP4493705A1
(en)
*
|
2022-03-16 |
2025-01-22 |
Rutgers, the State University of New Jersey |
Controlled muscle-specific gene delivery
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
EP4522757A2
(en)
|
2022-05-13 |
2025-03-19 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023250388A1
(en)
|
2022-06-22 |
2023-12-28 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
JP2025526502A
(ja)
*
|
2022-07-11 |
2025-08-13 |
ヴァイタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための治療用サテライト細胞の製造
|
|
JP2025535203A
(ja)
|
2022-09-15 |
2025-10-23 |
ボイジャー セラピューティクス インコーポレイテッド |
タウ結合化合物
|
|
WO2025014832A1
(en)
|
2023-07-07 |
2025-01-16 |
Kriya Therapeutics, Inc. |
Periocular delivery of aav vectors for treating ophthalmic pathologies
|